Speakers

Bernardo Arrospide is Operating Vice President with Accel-KKR, with focus in the Latin America and Iberia region. He is also a member of Accel-KKR’s DE&I council supporting the firm’s initiatives on Diversity, Equity, and Inclusion.

Prior to joining Accel-KKR, Bernardo was the co-founder and CEO of 4Vets, a venture-backed supply chain and procurement software business for the veterinary pharmaceutical industry in Brazil.  Bernardo was also previously the Chief of Staff to the CEO of the Medicines Company, a publicly traded biotech company acquired by Novartis in 2019.  While at the Medicines Company Bernardo led the company’s Latin America expansion strategy.  Bernardo started his career in Investment Banking at Goldman Sachs where he worked in both the New York and London offices.

Bernardo is involved with Accel-KKR’s investments in Estela, imed, Siigo, Lemontech and Endalia.

Bernardo received his M.B.A. with a specialization in Healthcare Management from the Wharton School, and his A.B. in Economics from the University of Chicago.

Accel-KKR is a technology-focused investment firm with over $14 billion in capital commitments. The firm focuses on software and IT-enabled businesses, well-positioned for topline and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across a wide range of transaction types including private company recapitalizations, divisional carve-outs and going-private transactions. Accel-KKR is headquartered in Menlo Park with additional offices in Atlanta, London, and Mexico City.